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ABSTRACT Two-tier serology testing is most frequently used for the diagnosis of
Lyme borreliosis (LB); however, a positive result is no proof of active disease. To es-
tablish a diagnosis of active LB, better diagnostics are needed. Tests investigating
the cellular immune system are available, but studies evaluating the utility of these
tests on well-deﬁned patient populations are lacking. Therefore, we investigated the
utility of an enzyme-linked immunosorbent spot (ELISpot) assay to diagnose active
Lyme neuroborreliosis. Peripheral blood mononuclear cells (PBMCs) of various study
groups were stimulated by using Borrelia burgdorferi strain B31 and various recombi-
nant antigens, and subsequently, the number of Borrelia-speciﬁc interferon gamma
(IFN-)-secreting T cells was measured. We included 33 active and 37 treated Lyme
neuroborreliosis patients, 28 healthy individuals treated for an early manifestation
of LB in the past, and 145 untreated healthy individuals. The median numbers of
B. burgdorferi B31-speciﬁc IFN--secreting T cells/2.5  105 PBMCs did not differ
between active Lyme neuroborreliosis patients (6.0; interquartile range [IQR], 0.5
to 14.0), treated Lyme neuroborreliosis patients (4.5; IQR, 2.0 to 18.6), and treated
healthy individuals (7.4; IQR, 2.3 to 14.9) (P  1.000); however, the median number
of B. burgdorferi B31-speciﬁc IFN--secreting T cells/2.5  105 PBMCs among un-
treated healthy individuals was lower (2.0; IQR, 0.5 to 3.9) (P  0.016). We conclude
that the Borrelia ELISpot assay, measuring the number of B. burgdorferi B31-speciﬁc
IFN--secreting T cells/2.5  105 PBMCs, correlates with exposure to the Borrelia
bacterium but cannot be used for the diagnosis of active Lyme neuroborreliosis.
KEYWORDS Borrelia burgdorferi, ELISpot, Lyme borreliosis, Lyme neuroborreliosis,
T-cell activation, active disease, antibodies, cytokines, diagnostics, interferon gamma
In the Netherlands, Lyme borreliosis (LB) poses a considerable threat to human health.A study among general practitioners (GPs) found a threefold increase of patients
reporting tick bites and diagnoses of erythema migrans (EM), an early, localized skin
rash, in the period between 1994 and 2009 (1). Between 2009 and 2014, the incidence
of reported tick bites ranged between 488 and 564 consultations per 100,000 inhab-
itants and the number of GP-reported diagnoses of EM ranged between 134 and 140
per 100,000 inhabitants (2). The true incidence rate is probably higher, since only a
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small part of the population consults a GP after a tick bite (3). Increased incidences of
LB have also been reported in several other European countries as well as in the United
States (4–6).
Diagnosis of active LB can be difﬁcult in the absence of a “gold standard” test, such
as PCR or culture. Exceptions are an EM, which is a clinical diagnosis, and acrodermatitis
chronica atrophicans (ACA) or Lyme arthritis, which can be supported by PCR and/or
culture. For Lyme neuroborreliosis, culture and PCR are too insensitive to be useful in
a routine clinical setting (7–10). The diagnosis of Lyme neuroborreliosis is based on
clinical symptoms and needs to be supported by laboratory tests. The most frequently
found clinical symptoms of Lyme neuroborreliosis are (lymphocytic) meningoradiculitis
and paresis (11); however, symptoms can be nonspeciﬁc, which often complicates the
diagnosis. Conﬁrmation of Lyme neuroborreliosis through laboratory testing consists of
the detection of Borrelia-speciﬁc antibodies in cerebrospinal ﬂuid (CSF) and an elevated
number of mononuclear cells in CSF, otherwise known as pleocytosis (5 leukocytes/
l) (11). Unfortunately, studies using well-characterized and unbiased patient groups
are rare and the sensitivity and speciﬁcity of the various tests can vary extensively (12).
The presence of intrathecally produced Borrelia-speciﬁc antibodies can indicate
active Lyme neuroborreliosis but also the persistence of Borrelia-speciﬁc antibodies
years after an asymptomatic or treated infection (13). The absence of Borrelia-speciﬁc
antibodies, on the other hand, does not rule out an active infection and can be
explained by the (low) sensitivity of the test used and the time it takes for the body to
produce detectable levels of Borrelia-speciﬁc antibodies after an infection (14). As early
and correct diagnosis of Lyme neuroborreliosis is essential for adequate treatment with
antibiotics (15–17), better diagnostic tools are warranted. The diagnostic shortcomings
underline the need for new diagnostic tests that can distinguish between active disease
and a previous, yet cleared, infection or that can aid in the diagnosis for those cases for
which the current diagnostics are insufﬁcient. In this study, active Lyme neuroborre-
liosis patients were used as a proxy for active disease.
In recent years, assays that focus on the cellular immune response for the diagnosis
of LB have become available. The cellular immune response against Borrelia is charac-
terized by a strong Th1 response, in which Borrelia activates Th1-like cytokines such as
interferon gamma (IFN-) (18–20). Elevated amounts of Th1-speciﬁc IFN- in blood,
synovial ﬂuid, and CSF of LB patients have been found in various studies (21–25).
However, compared to serology, T-cell assays were less sensitive and speciﬁc, and in
general these assays were not well standardized (10, 26). Despite the lack of published
studies on clinically validated cellular assays, various laboratories offer these assays for
the diagnosis of LB. These assays include the enzyme-linked immunosorbent spot
(ELISpot) assay (27) and the lymphocyte transformation test (LTT) (28). Therefore, the
clinical validation of these assays is urgently needed.
In this study, we performed the validation of a Borrelia ELISpot assay measuring the
number of IFN--producing T cells after stimulation with Borrelia burgdorferi B31.
Information regarding previous tick bites, symptoms, and antibiotic treatment for LB
was assessed by the completion of a Lyme-speciﬁc questionnaire and through con-
sulting electronic patient ﬁles. We used a standardized assay on well-deﬁned groups of
both treated and untreated patients and healthy controls to investigate whether the
number of Borrelia-speciﬁc T cells isolated from blood can be used as a marker for
disease activity.
MATERIALS AND METHODS
Study population. Whole-blood and serum samples were obtained from hospital patients diag-
nosed with active Lyme neuroborreliosis, hospital patients treated for Lyme neuroborreliosis in the past,
and healthy individuals (all 18 years old). All hospital patients diagnosed with Lyme neuroborreliosis in
Diakonessenhuis Hospital, Utrecht, and St. Antonius Hospital, Nieuwegein, the Netherlands, were eligible
for inclusion in the study if they fulﬁlled at least two criteria for Lyme neuroborreliosis as deﬁned by the
European Federation of Neurological Societies (EFNS) (11). These criteria are (i) the presence of neuro-
logical symptoms suggestive of Lyme neuroborreliosis without other obvious explanations, (ii) CSF
pleocytosis (5 leukocytes/l), and (iii) Borrelia-speciﬁc intrathecal antibody production. If all three
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criteria were met, a case was categorized as a deﬁnite Lyme neuroborreliosis case, and if two criteria were
met, a case was categorized as a possible Lyme neuroborreliosis case.
Hospital patients either were recently diagnosed with active Lyme neuroborreliosis or had been
treated previously for Lyme neuroborreliosis. Active Lyme neuroborreliosis patients were recruited from
December 2010 to December 2016 and were included if blood was drawn within 2 months after the start
of antibiotic therapy. In addition, active Lyme neuroborreliosis patients could also be included as treated
Lyme neuroborreliosis patients. To make sure that enough time had passed between both inclusions, at
least 1 year should have passed after they had ﬁnished treatment for their Lyme neuroborreliosis disease
episode. Treated Lyme neuroborreliosis patients, who had been diagnosed between February 2003 and
September 2014, were enrolled from January 2011 to March 2015 and were included at least 4 months
after completion of antibiotic therapy for Lyme neuroborreliosis.
Healthy individuals were recruited in the period between February 2013 and December 2015 from
personnel of Diakonessenhuis Hospital, Utrecht, St. Antonius Hospital, Nieuwegein, and the National
Institute for Public Health and the Environment (RIVM), Bilthoven, the Netherlands. Healthy individuals
also included Boy Scout patrol leaders, owners of hunting dogs, and recreational runners. All were invited
to participate if they pursued recreational activities in high-risk areas for tick bites. In addition, healthy
individuals who had received antibiotic treatment for an early manifestation of LB in the past, as they had
reported themselves in the Lyme-speciﬁc questionnaire, were analyzed as a separate group and are
referred to as treated healthy individuals.
All hospital patients and healthy individuals were asked to complete a Lyme-speciﬁc questionnaire.
This questionnaire included questions on tick bites, the presence of EM, antibiotic treatment for LB, and
self-reported complaints at the moment of inclusion and during possible earlier episodes of LB.
Information regarding the clinical symptoms, pleocytosis, and intrathecal antibody production during
active disease of the Lyme neuroborreliosis patients was extracted from the hospital information system.
Healthy individuals were recruited only if they reported no complaints at the time of the inclusion in the
study. All study participants gave their informed consent. The regional Medical Research Ethics Com-
mittees United approved the study (Nieuwegein, the Netherlands; MEC-U: NL36407.100.11).
Antibody detection in serum and serum-CSF pairs. Borrelia-speciﬁc serum antibodies were
detected using a two-tier serology protocol (29, 30). The ﬁrst test used was the C6 enzyme-linked
immunosorbent assay (ELISA) (Immunetics, Boston, MA, USA), which is based on a synthetic C6 peptide
and is derived from a highly immunogenic part (invariable region 6) of the VlsE (variable major
protein-like sequence, expressed) lipoprotein (31).
Equivocal and positive C6 ELISA results were conﬁrmed by using the recomLine immunoglobulin M
(IgM) and immunoglobulin G (IgG) immunoblot tests (Mikrogen GmbH, Neuried, Germany). The immu-
noblot strips detect antibodies against Borrelia burgdorferi sensu stricto, Borrelia afzelii, Borrelia garinii,
Borrelia bavariensis, and Borrelia spielmanii by using different recombinant antigens (32). Each recombi-
nant antigen has a certain value and will be counted when the intensity of the respective band is greater
than or equal to the intensity of the cutoff band. The following antigens, with their respective scores, are
used: p100 (IgM and IgG, 5 points each), VlsE (IgM and IgG, 5 points each), p58 (IgM and IgG, 4 points
each), p41 (IgM and IgG, 1 point each), p39 (IgM, 4 points, and IgG, 5 points), OspA (IgM and IgG, 5 points
each), OspC (IgM, 8 points, and IgG, 5 points), and p18 (IgM and IgG, 5 points each). Immunoblot results
were recorded as negative (5 points), equivocal (6 points), or positive (7 points). Immunoblotting was
performed according to the manufacturer’s instructions, and the results were recorded with an auto-
mated recomScan system using the recomScan software (Mikrogen GmbH). The ﬁnal immunoblot result
was based on a combination of the results of both immunoglobulins: negative when both IgM and IgG
were negative, equivocal when at least one of these was equivocal, and positive when at least one of
these was positive. When immunoblot conﬁrmation was performed, this result determined the ﬁnal
serology result, independent of an equivocal or positive C6 ELISA result.
Detection of intrathecally produced Borrelia-speciﬁc antibodies was done using the second-
generation IDEIA Lyme neuroborreliosis test (Oxoid, Hampshire, United Kingdom) (33). Antibody index
(AI) scores of0.3 were considered positive. The ﬁnal AI result was based on a combination of the results
of both immunoglobulins: negative when the AIs of both IgM and IgG were negative, equivocal when
at least one of these was equivocal, and positive when at least one of these was positive.
Both the C6 ELISA and the IDEIA Lyme neuroborreliosis test were performed according to the
manufacturer’s instructions using a Dynex DS2 automated ELISA instrument (Dynex Technologies), and
results were analyzed with DS-Matrix software (Dynex Technologies).
Borrelia ELISpot procedure. The Borrelia ELISpot assay was performed on peripheral blood isolated
from all study participants. The isolation of peripheral blood mononuclear cells (PBMCs) from whole-
blood specimens (lithium heparin) drawn 8 h before testing was done through density gradient
centrifugation (Hettich Rotanta 460 RS; rotor 5624) at room temperature for 15 min at 1,000  g using
Leucosep tubes (OxFord Immunotec Ltd., Abingdon, UK); however, for blood that was drawn between
8 and 32 h before testing, a T-cell Xtend (OxFord Immunotec Ltd.) step was performed following the
procedure described by Bouwman et al. (34) prior to PBMC isolation. After centrifugation, the PBMC
fraction was removed and washed twice. The ﬁrst wash step was performed at room temperature for7
min at 600  g; the second wash step was also performed at room temperature for 7 min at 300 
g. Both wash steps were performed in 10 ml of fresh, prewarmed (37°C) RPMI medium (Life Technologies,
Invitrogen, Bleiswijk, the Netherlands). If necessary, excess erythrocytes were removed between the ﬁrst
and second wash steps using human erythrocyte lysis buffer (0.010 M KHCO3, 0.0001 M EDTA, 0.150 M
NH4Cl [pH 7.3  0.1]). After addition of 5 ml of lysis buffer, the solution was incubated for 5 min at 2°C
and subsequently centrifuged using the ﬁrst wash step centrifugation program.
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The ﬁnal pellet was suspended in 1.1 ml of fresh, prewarmed (37°C) AIM-V medium (Life Technolo-
gies), and cells were counted using the AC.T diff 2 analyzer (Beckman Coulter, Woerden, the Netherlands).
Cells were adjusted to 2.5  106/ml and 100 l of that concentration was added to a precoated
polyvinylidene diﬂuoride (PVDF) ELISpotPRO well (Mabtech, Nacka Strand, Sweden). The negative control
consisted of 50 l of AIM-V medium, and as a positive control, 50 l (0.1 g/ml) of anti-human CD3
monoclonal antibody (MAb) CD3-2 (Mabtech) was used. To stimulate the cells, 50 l of a whole-cell lysate
(5 g/ml), a peptide mix (5 g/ml), and ﬁve recombinant antigens were tested (15 g/ml). The whole-cell
lysate tested was derived from B. burgdorferi strain B31 (Autoimmun Diagnostika GmbH, Straßberg,
Germany). The peptide mix (an Osp mix) consisted of a pool of 9-mer to 11-mer peptides of OspA (B.
burgdorferi, B. afzelii, and B. garinii), native OspC (B. afzelii), and recombinant p18 (Autoimmun Diagnos-
tika GmbH). The ﬁve recombinant antigens used were (i) p18 B. burgdorferi sensu stricto PKa, (ii) p18 B.
afzelii PKo, (iii) p18 B. garinii PBi, (iv) p39 B. afzelii PKo, and (v) p58 B. garinii PBi (Mikrogen GmbH), which
are also part of the recomLine immunoblot test (Mikrogen GmbH). The number of different antigens
tested depended on the yield of PBMCs. After 16 to 20 h at 37°C and 5% CO2, the wells were washed
using phosphate-buffered saline (PBS; pH 7.2  0.1) and incubated for 1 h at 2°C after addition of 50 l
of 7-B6-1–alkaline phosphatase (ALP) conjugate (Mabtech). The wells were washed again in PBS and
incubated with 50 l of 5-bromo-4-chloro-3=-indolylphosphate and nitroblue tetrazolium (BCIP/NBT) plus
substrate (Mabtech) for 7 to 10 min at room temperature.
Analysis of the Borrelia ELISpot assay results. The number of Borrelia-speciﬁc IFN--producing T
cells, displayed as black spots, was measured with an ELISpot reader (Autoimmun Diagnostika GmbH),
visually checked, and, if judged necessary, adjusted manually by two different operators in the EliSpot 6.0
software (Autoimmun Diagnostika GmbH). The spot size used was based on the expected spot size of an
IFN--producing T cell as determined by Feske et al. (35) and was set on 2.8 log (mm2). If there was a
difference in the T-cell count between the two operators of 4 spots for a certain sample, or if they
found any difference in spot count in the critical area (between 2 and 5 spots), then those samples were
recounted by a third operator, whose result was leading.
To determine the actual spot count due to the stimulation of T cells by Borrelia, the number of spots
in the negative-control well was subtracted from the number of spots in the antigen-stimulated well. The
number of spots corresponds with the number of individual T cells producing IFN- after antigen
stimulation. Different lot numbers of B. burgdorferi B31 lysate were used; however, they were derived
from the same batch of B. burgdorferi B31 lysate. If a blood sample was tested with 1 lot number, or
multiple times with an identical lot number, then the median spot count was calculated and used in the
Borrelia ELISpot analysis.
Data handling and statistical analysis. For statistical analyses, the IBM SPSS software package
(version 23) was used (IBM, Armonk, NY, USA). Dichotomous data were analyzed by using Pearson’s
chi-square test or Fisher’s exact test. The post hoc tests consisted of two-group comparisons by using
Pearson’s chi-square test or Fisher’s exact test using the Bonferroni correction. P values of 0.05 were
interpreted as statistically signiﬁcant. If the Bonferroni correction was applied, then a P value of 0.05/k
(for which k is the number of different hypotheses) was interpreted as statistically signiﬁcant. For
statistical analyses, equivocal serology results were combined with positive serology results.
Quantitative, unrelated data comparing 2 groups were analyzed by using the Kruskal-Wallis test,
and post hoc tests consisted of the Dunn-Bonferroni test. Quantitative, unrelated data comparing two
groups were analyzed using the Mann-Whitney test. Correlations were calculated using Spearman’s
correlation coefﬁcient (rs). Quantitative, related data comparing2 tests were analyzed using Friedman’s
related-samples two-way analysis of variance test, and post hoc tests consisted of the Dunn-Bonferroni
test. Quantitative, related data, comparing two tests, were analyzed using the Wilcoxon signed-rank test.
For all analyses, P values of 0.05 were interpreted as statistically signiﬁcant.
To determine the utility of the Borrelia ELISpot assay to diagnose active Lyme neuroborreliosis, a
receiver operating characteristic (ROC) curve was created to calculate the area under the curve (AUC).
Therefore, the number of Borrelia-speciﬁc IFN--secreting T cells among active Lyme neuroborreliosis
patients was compared with the number of Borrelia-speciﬁc IFN--secreting T cells among the other three
groups. Logistic regression was applied to investigate whether any additional risk factors could contrib-
ute to the diagnostic performance of the Borrelia ELISpot assay. The Hosmer-Lemeshow goodness-of-ﬁt
test was used to assess if the logistic regression model ﬁt the data. The outcome of the model was binary:
a case was either an active patient or a control. Figures were made with GraphPad Prism (version 5.04
for Windows; GraphPad Software, San Diego, CA, USA).
RESULTS
Study population. (i) Active Lyme neuroborreliosis patients. Thirty-three active
Lyme neuroborreliosis patients were included; their median age was 56.7 years (inter-
quartile range [IQR], 44.8 to 64.4 years). They were included before, during, or shortly
after antibiotic treatment started (median, 7.0 days after the start of antibiotic therapy;
IQR, 3.0 to 12.5 days) (Table 1). Antibiotic therapy consisted of intravenous ceftriaxone
for 14 or 30 days. Two patients switched to doxycycline because of an adverse reaction
to ceftriaxone. One patient was given doxycycline from the start (21 days). The clinical
symptoms among active Lyme neuroborreliosis patients mostly consisted of radicular
disease (15/33 [45.5%]) and/or cranial nerve paresis (15/33 [45.5%]).
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The majority of the active Lyme neuroborreliosis patients, 25/33 (75.8%), were
classiﬁed as deﬁnite Lyme neuroborreliosis patients and 8/33 (24.2%) of them as
possible Lyme neuroborreliosis patients, because they lacked production of intrathecal
antibody against Borrelia (Table 2). Only three patients had a positive antibody index
(AI) based on a solitary IgM response, 12 patients had positive AIs for both IgM and IgG,
and 10 patients had a positive AI based on a solitary IgG response (see Table S1 in the
supplemental material).
(ii) Treated Lyme neuroborreliosis patients. Thirty-seven Lyme neuroborreliosis
patients were included at a median of 5.0 years (IQR, 2.5 to 7.3 years) after they had
ﬁnished antibiotic therapy for LB (Table 1). The median age of the treated Lyme
neuroborreliosis patients at inclusion was 59.3 years (IQR, 49.4 to 66.9 years) (Table 1).
Antibiotic therapy consisted of intravenous ceftriaxone for 14 or 30 days; one patient
switched to doxycycline (for 14 days) due to an allergic reaction to ceftriaxone. Most
treated Lyme neuroborreliosis patients suffered from radicular disease (24/37 [64.9%])
and/or cranial nerve paresis (17/37 [45.9%]), which was similar to what was observed for
the active Lyme neuroborreliosis patients (Table 2).
Thirty-one (83.8%) out of the 37 treated Lyme neuroborreliosis patients were, when
they were diagnosed with active Lyme neuroborreliosis in the past, classiﬁed as deﬁnite
Lyme neuroborreliosis patients and 6/37 (16.2%) as possible Lyme neuroborreliosis
patients, of whom the majority did not have pleocytosis (5/6 [83.3%]) (Table 2). This was
in contrast with the active Lyme neuroborreliosis patients, who were, when diagnosed
with active Lyme neuroborreliosis, more often classiﬁed as possible Lyme neuroborre-
liosis patients, because of the absence of intrathecally produced Borrelia-speciﬁc anti-
TABLE 1 Demographic and clinical characteristics of the four study groupsa
Variable
Active Lyme NB
patientsb (n  33)
Treated Lyme NB
patientsb (n  37)
Treated healthy
individuals (n  28)
Untreated healthy
individuals (n  145)
P value
Overall 2-groupc
No. of males (%) 22 (66.7) 19 (51.4) 13 (46.4) 55 (37.9) 0.020 0.003k
Median age, yrs (IQR) 56.7 (44.8–64.4) 59.3 (49.4–66.9) 52.7 (38.1–57.5) 41.0 (27.0–51.7) 0.001 0.029l
Tick bite (%) 11 (45.8)d 27 (73.0) 26 (92.9) 87 (60.0) 0.001 0.041m
EM (n; %) 4 (16.7)d,e 9 (24.3)e 22 (78.6)h 4 (2.8)j 0.001 0.015n
No. of positives in two-tier serology
testing (%)
30 (90.9) 6 (16.7)g 5 (17.9) 18 (12.4) 0.001 0.001o
IgM (n; %) 16 (48.5) 3 (8.3) 2 (7.1) 1 (0.7) 0.001 0.025p
IgG (n; %) 28 (84.8) 6 (16.7) 3 (10.7) 18 (12.4) 0.001 0.001q
Median time between end of AB and
blood sampling, yrs (IQR)
NA 5.0 (2.5–7.3) 5 (2–7)i NA NA 0.563
Median time between start of AB and
blood sampling, days (IQR)
7.0 (3.0–12.5) NA NA NA NA NA
Self-reported complaints at inclusion See Table 2f 23 (62.2%) 0 0 NA NA
aEM, erythema migrans; AB, antibiotic treatment for Lyme borreliosis; IQR, interquartile range; NB, neuroborreliosis; n, number of study participants; NA, not applicable.
bSix active Lyme neuroborreliosis patients were also included as treated neuroborreliosis patients (1 year after they had ﬁnished treatment for their Lyme
neuroborreliosis disease episode).
cFor all two-group comparisons with a signiﬁcant difference, the Bonferroni correction was applied.
dNine (27.3%) active Lyme neuroborreliosis patients did not complete the Lyme-speciﬁc questionnaire, so data on tick bite and/or EM were not present for them.
eOne patient with erythema migrans did not recall a tick bite; all others did recall a tick bite.
fFor active Lyme neuroborreliosis patients, instead of the self-reported complaints, we assessed the electronic patients ﬁles for clinical symptoms due to Lyme
neuroborreliosis. Those symptoms are listed in Table 2.
gFor one (2.7%) treated Lyme neuroborreliosis patient, two-tier serology testing was not done because of the lack of a serum sample.
hTwo individuals with erythema migrans did not recall a tick bite and six individuals did not report an erythema migrans and were treated for an atypical skin rash
(n  4), ﬂu-like symptoms after the tick bite (n  1), or the presence of an engorged adult tick (n  1).
iOne (3.6%) individual who did not know when antibiotic treatment took place was excluded.
jAll individuals with erythema migrans recalled a tick bite.
kUntreated healthy individuals versus active Lyme neuroborreliosis patients.
lUntreated healthy individuals versus all other groups.
mTreated healthy individuals versus all other groups (P  0.041); treated Lyme neuroborreliosis patients versus active Lyme neuroborreliosis patients (P  0.033).
nTreated healthy individuals versus all other groups (P  0.001); untreated healthy individuals versus both Lyme neuroborreliosis patient groups (P  0.015).
oActive Lyme neuroborreliosis patients versus all other groups.
pActive Lyme neuroborreliosis patients versus all other groups (P  0.001); untreated healthy individuals versus treated Lyme neuroborreliosis patients (P  0.025).
qActive Lyme neuroborreliosis patients versus all other groups.
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bodies (P  0.010) (Table 2). A total of 36 (97.3%) of the 37 treated Lyme neurobor-
reliosis patients had a positive AI for IgG, of whom 17 (47.2%) also had a positive AI for
IgM (data not shown). Interestingly, 23/37 (62.2%) of the treated Lyme neuroborreliosis
patients still reported complaints when they were included in this study (Table 1). These
self-reported complaints included neuropathic complaints, cognitive complaints, fa-
tigue, myalgias, paraesthesias, and/or malaise. A total of six treated Lyme neuroborre-
liosis patients had also been included as active Lyme neuroborreliosis patients at the
time they were diagnosed with active Lyme neuroborreliosis; the median time between
the end of antibiotic treatment for Lyme neuroborreliosis and inclusion in this study as
a treated Lyme neuroborreliosis patient was 2.3 years (IQR, 1.6 to 2.7 years).
(iii) Healthy individuals. One hundred seventy-three healthy individuals were
included; their median age at inclusion was 42.2 years (IQR, 27.5 to 53.2 years).
Twenty-eight (16.2%) out of these individuals reported antibiotic therapy for LB in the
past (median, 5 years ago; IQR, 2 to 7 years), and they were classiﬁed separately as
treated healthy individuals (Table 1). Most treated healthy individuals reported antibi-
otic treatment for EM (22/28 [78.6%]); the six remaining individuals were treated for an
atypical skin rash (n  4), ﬂu-like symptoms after the tick bite (n  1), or the presence
of an engorged adult tick (n  1). The remaining 145 (83.8%) healthy individuals were
classiﬁed as untreated healthy individuals. The median age of the treated healthy
individuals was 52.7 years (IQR, 38.1 to 57.5 years). In this group, the percentage of tick
bites was higher than in all other groups (P  0.041). Comparison of the four study
groups showed that the percentage of EM was also highest among treated healthy
individuals (22/28 [78.6%]) (P 0.001) (Table 1). The untreated healthy individuals were
younger than the other three groups (median, 41.0 years; IQR, 27.0 to 51.7 years) (P 
0.029), and 87/145 (60.0%) recalled a tick bite; four of them also mentioned an EM. The
percentage of reported EM within this group was lower than for all other groups (P 
0.015) (Table 1).
Two-tier serology results. Serology testing showed that most of the active Lyme
neuroborreliosis patients were seropositive (30/33 [90.9%]) (Table 1). Twenty-eight
(84.8%) of the 33 seropositive patients had IgG antibodies; 16/33 (48.5%) also had IgM
antibodies (Table 1). Only two active Lyme neuroborreliosis patients had a positive
serology result based on a solitary IgM response. Both IgM and IgG were more often
found among active Lyme neuroborreliosis patients than among the other three
groups (P  0.001 for both) (Table 1).
For 36/37 treated Lyme neuroborreliosis patients, a serum sample was available for
serology; 6/36 (16.7%) had a positive result (Table 1). For all six cases, the result was
based on an IgG response; three of them also had an IgM response (Table 1). Interest-
ingly, no difference was found in serology among treated Lyme neuroborreliosis
patients with and without complaints (P  1.000; data not shown). Only 4 (17.4%) out
of the 23 treated Lyme neuroborreliosis patients with complaints had Borrelia-speciﬁc
antibodies, and 2 (15.4%) out of the 13 treated Lyme neuroborreliosis patients without
complaints were seropositive (the serum of one patient without complaints was
missing). The two-tier serology of the six patients that were included both as an active
Lyme neuroborreliosis patient and later as a treated Lyme neuroborreliosis patient
showed that four (66.7%) out of the six patients reverted from seropositive to serone-
gative. These six patients all had Lyme neuroborreliosis-speciﬁc symptoms at the time
of their diagnosis with active disease (all had radicular disease; two had facial nerve
paresis as well, of whom one also had meningitis). These Lyme neuroborreliosis-speciﬁc
symptoms had all disappeared at the time they were included in the study as a treated
Lyme neuroborreliosis patient. Two (33.3%) of them did not report any complaints at
all, but four (66.7%) reported nonspeciﬁc symptoms, such as fatigue (n  2), loss of
focus and/or amnesia (n  2), loss of strength (n  1), early-onset rheumatoid arthritis
(n  1), urinary problems (n  1), and arrhythmia (n  1).
Among the 173 healthy individuals, a total of 23 (13.3%) had Borrelia-speciﬁc serum
antibodies. Positive serology results were found among both treated and untreated
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healthy individuals (5/28 [17.9%] and 18/145 [12.4%], respectively) (Table 1). Among
treated healthy individuals, positive serology results were based on either an IgG
response (3/5 [60.0%]) or an IgM response (2/5 [40.0%]). Among untreated healthy
individuals, all 18 positive serology results were based on an IgG response; only 1 (5.6%)
of them also had an IgM response (Table 1). All 23 healthy individuals with a positive
serology result were invited to consult an infectious diseases specialist, and 17 (73.9%)
of them did indeed visit the specialist. None of them had any signs or symptoms
suggesting a current or recent (symptomatic) LB.
Performance of the Borrelia ELISpot assay with different Borrelia antigens.
Analysis of the ﬁnal spot counts of both operators showed that one operator system-
atically had higher spot counts. The correlation between both operators, however, was
very high (rs, 0.913; P  0.001).
All 243 study participants were tested with B. burgdorferi B31 whole-cell lysate; a
subset of study participants was also tested with the other Borrelia antigens (Table 3).
In general, stimulation with Osp mix resulted in fewer IFN--secreting T cells/2.5  105
PBMCs than stimulation with B. burgdorferi B31 (P  0.001 [all study participants] and
P 0.028 [within the study groups]) (Table 3). A similar trend was seen for the different
recombinant antigens compared to B. burgdorferi B31 (P 0.001 [all study participants]
and P  0.020 [within the study groups]) (Table 3). Interestingly, only for active Lyme
neuroborreliosis patients was an association found between the number of Osp
mix-speciﬁc IFN--secreting T cells/2.5  105 PBMCs and the number of B. burgdorferi
B31-speciﬁc IFN--secreting T cells/2.5  105 PBMCs (rs, 0.723; P  0.001; n  21) (data
not shown). Since the B. burgdorferi B31 lysate resulted in the highest number of
IFN--secreting T cells/2.5  105 PBMCs, those results were used in all further (statis-
tical) analyses.
Borrelia ELISpot assay results by study group and self-reported complaints. No
signiﬁcant difference was found in the number of B. burgdorferi B31-speciﬁc IFN--
secreting T cells/2.5  105 PBMCs between the following three groups: active Lyme
neuroborreliosis patients (median, 6.0; IQR, 0.5 to 14.0), treated Lyme neuroborreliosis
patients (median, 4.5; IQR, 2.0 to 18.6), and treated healthy individuals (median, 7.4; IQR,
2.3 to 14.9) (P  1.000) (Fig. 1). However, these three groups had higher numbers of B.
burgdorferi B31-speciﬁc IFN--secreting T cells/2.5 105 PBMCs than untreated healthy
individuals (median, 2.0; IQR, 0.5 to 3.9) (P  0.016) (Table 3).
More than 60% of the treated Lyme neuroborreliosis patients reported one or more
symptoms in the Lyme-speciﬁc questionnaire (Table 1); however, no correlation was
found between these self-reported symptoms and the number of B. burgdorferi B31-
speciﬁc IFN--secreting T cells/2.5  105 PBMCs (rs, 0.200; P  0.235). The reactivity
found among treated healthy individuals also could not be linked to symptomatic
disease, since none of the healthy individuals reported any complaints.
Diagnostic performance of the Borrelia ELISpot assay. To assess the diagnostic
performance of the Borrelia ELISpot assay for detecting active Lyme neuroborreliosis,
we used a logistic regression model. In the ﬁrst model, only the results of the Borrelia
ELISpot assay were used. The outcome of the model was used to create a receiver
operating characteristic (ROC) curve. Unfortunately, the area under the curve (AUC)
found was only slightly better than a random predictor (model 1; AUC, 0.591) (Fig. 2)
and the model did not ﬁt the data (P  0.026) (see Table S2 in the supplemental
material).
To determine the (added) value of various risk factors, we also investigated other
logistic regression models. The following risk factors were assessed: sex, tick bite, EM,
and age (see Table S2). Interestingly, when a model was created for which only the risk
factors tick bite and age were included, and thus without the results of the Borrelia
ELISpot assay, a better AUC was achieved (model 2; AUC, 0.689) (Fig. 2; see also Table
S2). Addition of the Borrelia ELISpot assay results to the risk factors of model 2 only
minimally increased the AUC (model 3; AUC, 0.694) (Fig. 2; see also Table S2). When all
risk factors were included in the model, an AUC of 0.741 was found (model 4). Taking
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into account all possible interaction effects, only “age by Borrelia ELISpot” was signif-
icant (P 0.018), and adding this to model 4 resulted in an AUC of 0.769 (model 5) (Fig.
2; see also Table S2). In the last model, the absence of a tick bite increased the odds of
being an active Lyme neuroborreliosis patient (odds ratio [OR], 2.938; P  0.029). The
contribution of the Borrelia ELISpot assay result (OR, 1.218; P  0.010), age (OR, 1.061;
P 0.001), and the interaction term “age by Borrelia ELISpot” (OR, 0.996; P 0.018) was
minimal in this model (see Table S2).
Borrelia ELISpot assay versus two-tier serology. In general, seropositive cases had
a higher number of B. burgdorferi B31-speciﬁc IFN--secreting T cells/2.5  105 PBMCs
(median, 5.0; IQR, 1.5 to 14.0) than seronegative cases (median, 2.0; IQR, 1.0 to 5.0) (P 
0.005) (Table 4). When the four study groups were analyzed separately, no signiﬁcant
difference was found in the number of B. burgdorferi B31-speciﬁc IFN--secreting T
cells/2.5  105 PBMCs between seropositive and seronegative cases (P  0.070 to
1.000) (Table 4). Interestingly, among seronegative study participants, less B. burgdorferi
B31-speciﬁc T-cell activity was found among untreated healthy individuals than in both
treated groups (P  0.001) (data not shown); no difference was found among the
seropositive study participants between the four study groups (P  0.216) (data not
shown). Analysis of the C6 ELISA index scores, which are semiquantitative, showed an
association between the level of the C6 ELISA index scores and the number of
Borrelia-speciﬁc T cells (rs, 0.187; P  0.004); however, no association was found within
any of the four groups (data not shown).
Borrelia ELISpot assay versus antibody index for active Lyme neuroborreliosis
patients. Because of the prerequisite of a CSF sample to determine the antibody index,
AIs were determined only for Lyme neuroborreliosis patients at the time of diagnosis
and thus were lacking for the healthy individuals. Only for active cases were the AI and
Borrelia ELISpot assay results from samples from the same time period available and
thus comparable and could be used in subsequent analyses. No difference was found
FIG 1 B. burgdorferi B31-speciﬁc T-cell activation among active Lyme neuroborreliosis patients, treated
Lyme neuroborreliosis patients, treated healthy individuals, and untreated healthy individuals. ANB,
active Lyme neuroborreliosis patients; TNB, treated Lyme neuroborreliosis patients; THI, treated healthy
individuals; UHI, untreated healthy individuals; n, number of study participants. *, signiﬁcant difference
based on a P value of 0.001; **, signiﬁcant difference based on a P value of 0.016.
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among active Lyme neuroborreliosis patients when the numbers of B. burgdorferi
B31-speciﬁc IFN--secreting T cells/2.5  105 PBMCs were compared between
AI-positive and AI-negative cases (P 0.550) (see Table S1). Similarly, no difference was
found among the active patients when the numbers of B. burgdorferi B31-speciﬁc
IFN--secreting T cells/2.5 105 PBMCs were compared between negative and positive
IgM AI results or between negative and positive IgG AI results (P  0.081 and 0.336,
respectively) (see Table S1). The lack of an association between the number of B.
burgdorferi B31-speciﬁc IFN--secreting T cells/2.5  105 PBMCs and the level of AI
scores of both IgM and IgG was conﬁrmed using Spearman’s correlation coefﬁcient
(rs  0.109 and P  0.575 for IgM and rs  0.054 and P  0.764 for IgG). We did,
FIG 2 Receiver operating characteristic (ROC) curve of the Borrelia ELISpot assay results and selected
logistic regression models that improved the diagnostic performance of the Borrelia ELISpot assay used
in this study. The ROC curve of model 1 is based on the number of B. burgdorferi B31-speciﬁc
IFN--secreting T cells/2.5  105 PBMCs (the Borrelia ELISpot assay). Model 2 is based solely on the risk
factors tick bite and age and thus is without the addition of the Borrelia ELISpot assay results. Model 3
is based on model 2, with the addition of the Borrelia ELISpot assay results. Model 4 is based on all risk
factors analyzed in this study (i.e., sex, tick bite, EM, and age, in addition to the Borrelia ELISpot assay
results), and model 5 is based on model 4 with the addition of the interaction term “age by Borrelia
ELISpot” (see also Table S2).
TABLE 4 Overview of the number of B. burgdorferi B31-speciﬁc IFN--secreting T cells
among study participants with and without Borrelia-speciﬁc serum antibodies
Group
Serology
result n
No. of B. burgdorferi
B31-speciﬁc IFN--
secreting T cells/
2.5  105 PBMCs
P valueMedian IQR
All combined  183 2.0 1.0–5.0
0.005b
	 59 5.0 1.5–14.0
Active Lyme NB patients  3 5.0 2.5–19.5
1.000
	 30 6.0 0.8–13.5
Treated Lyme NB patientsa  30 5.5 2.0–18.1
0.664
	 6 4.3 3.5–36.6
Treated healthy individuals  23 6.0 1.5–14.0
0.121
	 5 15.0 4.0–34.0
Untreated healthy individuals  127 1.5 0.5–3.8
0.070
	 18 3.0 1.0–6.3
aFor one treated Lyme neuroborreliosis patient, two-tier serology testing was not done because of the lack
of a serum sample.
bSeronegative study participants had signiﬁcantly lower numbers of B. burgdorferi B31-speciﬁc IFN--
secreting T cells/2.5  105 peripheral blood mononuclear cells than seropositive study participants.
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however, ﬁnd a negative correlation between the level of the AI score for IgM and the
number of B. burgdorferi B31-speciﬁc IFN--secreting T cells/2.5  105 PBMCs when
only those active patients who had a positive AI for IgM were analyzed (n  12; rs,
0.694; P  0.012). No such association was found for IgG (data not shown).
DISCUSSION
In this study, we used well-deﬁned patient populations and healthy controls to
evaluate the utility of the Borrelia ELISpot assay. We found that the number of B.
burgdorferi B31-speciﬁc IFN--secreting T cells/2.5 105 PBMCs in peripheral blood was
signiﬁcantly elevated in active Lyme neuroborreliosis patients, treated Lyme neurobor-
reliosis patients, and healthy individuals treated for early manifestations of LB in the
past compared to untreated healthy individuals (P  0.016). Thus, positive Borrelia
ELISpot assay results are, in general, associated with exposure and/or (past) infection
with B. burgdorferi sensu lato. The diagnostic performance of the Borrelia ELISpot assay
for the detection of active disease was determined by calculation of the ROC curve,
which resulted in an AUC of 0.591, suggesting that this assay is unsuitable for the
diagnosis of active Lyme neuroborreliosis.
To diagnose Lyme neuroborreliosis, laboratories often rely upon the detection of
intrathecally produced Borrelia-speciﬁc antibodies. The Borrelia ELISpot assay, however,
did not outperform the AI assay, as the Borrelia ELISpot assay results among active
Lyme neuroborreliosis patients did not differ between AI-positive and AI-negative
patients (P  0.550). We did, however, ﬁnd a negative correlation among positive
AI scores for IgM and the number of B. burgdorferi B31-speciﬁc IFN--secreting T
cells/2.5  105 PBMCs in peripheral blood (rs, 0.694; P  0.012). This is in line with
the results found by Dattwyler et al. (36, 37), who showed that a Borrelia-speciﬁc T-cell
response precedes the development of a measurable antibody response.
In this study, we found that whole-cell lysates of B. burgdorferi B31 yielded more
activated T cells when used to stimulate the PBMCs than when various recombinant
antigens were used for PBMC stimulation. This could be explained by the higher
number of antigens present in whole-cell lysates and, hence, more antigenic determi-
nants that can elicit an immune response than the (limited) number of antigenic
determinants present among the recombinant antigens used. von Baehr et al. (38) also
reported that a whole-cell lysate stimulated PBMCs better than recombinant antigens.
We cannot, however, exclude the possibility that the amount of recombinant antigens
we used was too low.
We found Borrelia ELISpot assay reactivity among treated Lyme neuroborreliosis
patients and treated healthy individuals, but this could not be linked to symptoms,
although more than 60% of the treated Lyme neuroborreliosis patients in this study still
reported (nonspeciﬁc) symptoms. Similar percentages have been found in other studies
(39–41). The nonspeciﬁc symptoms reported among treated Lyme neuroborreliosis
patients could not be linked to the Borrelia ELISpot assay results. The Borrelia ELISpot
assay reactivity among the treated healthy individuals could also not be linked to
complaints, as these individuals were included in the study only when they reported
having no complaints at all. Therefore, we conclude that the Borrelia ELISpot assay
reactivity among both treated groups is most likely explained by a previous, cured LB.
Borrelia ELISpot assay reactivity was also found among untreated healthy individu-
als. Ekerfelt et al. (42) also found elevated numbers of Borrelia-speciﬁc IFN--secreting
T cells in both clinical LB cases and asymptomatic (seropositive) controls after stimu-
lation with an outer surface-enriched fraction of B. afzelii. In our study, the number of
B. burgdorferi B31-speciﬁc IFN--secreting T cells/2.5  105 PBMCs did not differ
between seropositive and seronegative untreated healthy individuals (P  0.070). This
could be explained by the low number of seropositive cases (18 seropositive cases
versus 127 seronegative cases), although Dattwyler et al. (43) did report an increased
T-cell proliferative response to whole-cell B. burgdorferi among active LB patients who
did not have Borrelia-speciﬁc antibodies. Borrelia ELISpot assay reactivity among un-
treated, seronegative healthy individuals could also be explained by the choice of the
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antigen. It is known that the use of whole-cell lysates increases the chance of cross-
reactivity, which could lead to false-positive results. The B. burgdorferi B31 lysate used
contains antigens such as ﬂagellin, which shows high homology with antigens from
Treponema pallidum or bacteria of the genus Leptospira. To investigate for possible
cross-reactivity, we also tested the blood of some patients with active neurosyphilis
(n  2) and active leptospirosis (n  2), and a strong ELISpot assay reactivity against B.
burgdorferi B31 was found for one leptospirosis case, but the patients with neurosyph-
ilis did not show Borrelia ELISpot assay reactivity (data not shown). Lipopolysaccharides
(LPS) present in whole-cell lysates could also potentially stimulate the T cells, although
Janský et al. (18) showed that LPS from Escherichia coli did not result in elevated IFN-
levels and that Borrelia lysates did. Other studies showed the production of IFN- by NK
cells after stimulation with LPS (44, 45); however, we tried to correct for this phenom-
enon by adjusting the ELISpot assay reader settings in which we omitted small- and
low-intensity spots (35, 46).
Apart from the possible false-positive results, false-negative results were also found,
as samples from some active Lyme neuroborreliosis patients did not show Borrelia
ELISpot assay reactivity. This could be explained by the type of species used to
stimulate the T cells, since B. garinii and B. bavariensis have been linked to Lyme
neuroborreliosis more often than B. burgdorferi, and B. afzelii has been isolated from
CSF of Lyme neuroborreliosis patients as well (47, 48). Since all aforementioned Borrelia
species are closely related and share many antigens, they will most likely be cross-
reactive when used in the Borrelia ELISpot assay. Therefore, we decided to test the B.
burgdorferi B31 lysate, supported by the results of von Baehr et al. (38) and Nordberg
et al. (49). von Baehr et al. tested three different Borrelia species in a lymphocyte
transformation test and did not ﬁnd any differences between these species. Nordberg
et al. used B. garinii as a stimulating agent in an ELISpot assay among Lyme neurobor-
reliosis patients and obtained results which were comparable with the results of the B.
burgdorferi B31 ELISpot assay we tested. The relatively low numbers of B. burgdorferi
B31-speciﬁc IFN--secreting T cells/2.5  105 PBMCs among active Lyme neuroborre-
liosis patients in our study could also be explained by the compartmentalization of T
cells to the CSF. Several studies have shown that patients with neurological LB had less
T-cell reactivity against Borrelia in peripheral blood than other manifestations of LB (22,
23). Analysis of the T-cell response in CSF and blood in a subset of patients who had
neurological LB also showed a higher number of Borrelia-speciﬁc IFN--secreting T cells
in CSF than in blood (22). Still, analysis of CSF did not result in a better diagnostic
performance, as has been shown by Nordberg et al. (49), who found a sensitivity of 36%
and a speciﬁcity of 82% using ﬁve spots.
In our study, we included only active Lyme neuroborreliosis patients as deﬁned by
the EFNS criteria (11). These criteria are clear and easy to apply. Most active and treated
Lyme neuroborreliosis patients in this study were deemed to have deﬁnite Lyme
neuroborreliosis at the time of diagnosis (75.8% and 83.8%, respectively), and therefore,
we feel conﬁdent that we were dealing with true LB cases. We used the active Lyme
neuroborreliosis patients as a proxy for active LB; however, we realize that it is difﬁcult
to extrapolate the results found in this study to other manifestations of LB. Future
studies should therefore include patients with other manifestations of LB as well. Our
research group has started to include Lyme arthritis cases since the beginning of 2015
and intends to include other LB manifestations, such as EM, Lyme lymphocytoma, or
ACA, in 2018 as well.
This study had various limitations. A difference was found in sex and age between
the four study groups. Patients with active Lyme neuroborreliosis were more often male
and were older than untreated healthy individuals, which is most likely explained by
the way of recruitment, as most healthy individuals were recruited in our hospital,
increasing the likelihood of inclusion of more (young) females. The results of the logistic
regression model, however, did not show any signiﬁcant attribution for sex, and the
contribution of age was minimal (OR, 1.061; P  0.001).
The way of recruitment also led to the inclusion of increased numbers of healthy
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individuals with a past tick bite and/or EM. The results of the logistic regression model
indeed showed that the absence of a tick bite could aid in diagnosing active Lyme
neuroborreliosis. Although most likely biased, there could be some logic in the con-
tribution of this risk factor in developing active Lyme neuroborreliosis, because not
noticing a tick bite could increase the chance of developing disseminated LB. One
would expect individuals who did notice a tick bite to be more alert for development
of any symptoms suggesting LB, and those individuals would consequently seek
medical advice if they developed such symptoms. They are, therefore, less likely to
develop disseminated LB.
The way of recruitment of the three control groups, which included treated Lyme
neuroborreliosis patients as well as healthy individuals with a previously treated
early manifestation of LB and/or an increased risk of contact with the Borrelia
bacterium, resulted in increased Borrelia ELISpot assay reactivity and thus lower
speciﬁcity. Therefore, further studies should include cohorts with lower prevalences,
as well as other (cross-reacting) diseases to better assess the speciﬁcity of the
Borrelia ELISpot assay.
Unfortunately, not much is known about the T-cell dynamics after treatment, and
controversial data have been published regarding this subject (23, 50, 51). Therefore,
this needs to be further elucidated, and we are currently monitoring the active Lyme
neuroborreliosis patients both serologically and immunologically (through Borrelia
ELISpot assay) at different time points up to 2 years after inclusion. This way we hope
to get more information regarding the T-cell dynamics.
Finally, a total of six patients were included twice in this study, both as active Lyme
neuroborreliosis patients and, at a later time point (1.6 years later), as treated Lyme
neuroborreliosis patients. As 66.7% turned seronegative and Lyme-speciﬁc symptoms
at the time of active disease had disappeared and the individuals showed either
nonspeciﬁc symptoms or a complete recovery, we do not believe that this created a
bias.
In conclusion, the Borrelia ELISpot assay used in this study, measuring the number
of B. burgdorferi B31-speciﬁc IFN--secreting T cells, cannot be used for the diagnosis of
active Lyme neuroborreliosis.
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